Purple Biotech Anticipates Key Clinical Milestones

Purple Biotech (PPBT) has released an update.

Purple Biotech, a company listed on NASDAQ/TASE under the symbol PPBT, has reinforced its financial position, boasting a $7.3 million cash balance and expecting multiple clinical data readouts in 2024. The company is focused on developing first-in-class drugs for cancers with high unmet medical needs, including promising candidates for pancreatic cancer and a preclinical tri-specific immuno-engagers platform. With a lean global operation, Purple Biotech anticipates a cash runway into the third quarter of 2025, suggesting a strong footing for upcoming clinical trials and drug development initiatives.

For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.